Morar Mitrica, Sorina, Pohl, Thomas, Theisen, Dietmar, Boll, Björn, Bechtold-Peters, Karoline, Schipflinger, Reinhard, Beyer, Beate, Zierow, Swen, Kammueller, Michael, Pribil, Andreas, Schmelzer, Bernhard, Boehm, Stephan, Goetti, Micheline and Serno, Tim (2023) An Intra-Company Analysis of Inherent Particles in Biologicals Shapes the Protein Particle Mitigation Strategy Across Development Stages. Journal of pharmaceutical sciences. ISSN 00223549

Abstract

To better understand protein aggregation and inherent particle formation in the biologics pipeline at Novartis, a cross-functional team collected and analyzed historical protein particle issues. Inherent particle occurrences from the past 10 years were systematically captured in a protein particle database. Where the root cause was identified, a number of product attributes (such as development stage, process step, or protein format) were trended. Several key themes were revealed: 1) there was a higher propensity for inherent particle formation with non-mAbs than with mAbs; 2) the majority of particles were detected following manufacturing at scale, and were not predicted by the small-scale studies; 3) most issues were related to visible particles, followed by subvisible particles; 4) 50% of the issues were manufacturing related. These learnings became the foundation of a particle mitigation strategy across development and technical transfer, and resulted in a set of preventive actions. Overall, this study provides further insight into a recognized industry challenge and hopes to inspire the biopharmaceutical industry to transparently share their experiences with inherent particles formation.

Item Type:	Article
Date Deposited:	02 Mar 2023 00:45
Last Modified:	02 Mar 2023 00:45
URI:	https://oak.novartis.com/id/eprint/48480